Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)/ Covid-19

Next Previous
Trial Profile

Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)/ Covid-19

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anakinra (Primary) ; Apremilast (Primary) ; Eritoran (Primary) ; Hydroxychloroquine (Primary) ; Interferon beta-1a (Primary) ; Lopinavir/ritonavir (Primary) ; Mercaptamine (Primary) ; Sarilumab (Primary) ; Tocilizumab (Primary) ; TRV 027 (Primary) ; Amoxicillin/clavulanic acid; Ascorbic acid; Aspirin; Azithromycin; Azithromycin; Baloxavir-marboxil; Baricitinib; Ceftaroline fosamil; Ceftriaxone; Clarithromycin; Clarithromycin; Clopidogrel; Convalescent anti-SARS-CoV-2 plasma; Dalteparin sodium; Dalteparin sodium; Dexamethasone; Dexamethasone; Erythromycin; Heparin; Hydrocortisone; Interferon beta-1; Levofloxacin; Lopinavir; Lopinavir; Low molecular weight heparins; Macrolides; Moxifloxacin; Oseltamivir; Piperacillin/tazobactam; Plasma; Prasugrel; Ritonavir; Roxithromycin; Simvastatin; Ticagrelor; Vitamins
  • Indications Community-acquired pneumonia; COVID 2019 infections; COVID-19 pneumonia; Influenza virus infections; SARS-CoV-2 acute respiratory disease
  • Focus Therapeutic Use
  • Acronyms AD-SCAP; REMAP-CAP; REMAP-COVID

Most Recent Events

  • 01 Apr 2025 According to results published in the Intensive Care Medicine Fixed 7-day course hydrocortisone enrollment was stopped for futility (< 5% probability of > 20% relative improvement).
  • 01 Apr 2025 Results assessing Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia published in the Intensive Care Medicine
  • 25 Oct 2023 Results published in the New England Journal of Medicine

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top